Cryopreserved ampule of Normal Human Dendritic Cells (NHDC) containing ≥2.5 million cells
Cryopreserved ampule of Human Peripheral Blood CD14+ Monocytes, positive selection, containing ≥10 million cells
Do you need a modified version of this cell product, such as different vialing sizes, matched immune cell isolations or isolations from special donors or species? Contact Lonza CellBio Services to discuss custom isolation, expansion, and testing options for your research
Cryopreserved ampule of Human Peripheral Blood CD14+ Monocytes, positive selection, containing ≥20 million cells
Do you need a modified version of this cell product, such as different vialing sizes, matched immune cell isolations or isolations from special donors or species? Contact Lonza CellBio Services to discuss custom isolation, expansion, and testing options for your research
Cryopreserved ampule of Human Peripheral Blood CD14+ Monocytes, positive selection, containing ≥40 million cells
Do you need a modified version of this cell product, such as different vialing sizes, matched immune cell isolations or isolations from special donors or species? Contact Lonza CellBio Services to discuss custom isolation, expansion, and testing options for your research
Cryopreserved human leukapheresis product (≥9.5 billion cells)
Cryopreserved human leukapheresis product (≥5.0 billion cells)
Cryopreserved ampule of Human Peripheral Blood Mononuclear Cells (hPBMC) containing ≥ 50 million cells with cell population frequency information
Cryopreserved ampule of Human Peripheral Blood Mononuclear Cells (hPBMC) containing ≥ 100 million cells with cell type frequency information
-
Using Serum-free Media to Streamline CAR T-Cell Manufacturing WorkflowsLearn from this peer reviewed article, published in Cell and Gene Therapy Insights, how serum-free media can support large-scale, regulatory compliant expansion of CAR T-Cells.
-
Synthego-Lonza Genome Editing of Resting T cellsCase Study on Genome Editing of Resting T cells
-
Evaluating Performance of Cryopreserved PBMCsQuality of Lonza PBMCS in comparison to competitors
-
Therapeutic Approaches to Enhance Natural Killer Cell Cytotoxicity: The Force AwakensPoster published by Nature Reviews Drug Discovery, sponsored by Lonza. Natural killer (NK) cells are emerging as attractive candidates for new immunotherapeutic approaches. The poster shows the approaches to NK cell tumor targeting.
-
Bioscience Solutions Catalog 2018Catalog-Chapter6-Transfection-2018.pdf
-
Cryopreserved Human LeukopakA brief guide and introduction to Lonza Cryopreserved Leukopak
-
Bioscience Solutions Catalog 2018Catalog-Chapter2-Primary-Cells-2018.pdf
-
Normal Peripheral Blood CD4+ T LymphocytesLonza Application Notes
-
TechSheet - X-VIVO™ Media SystemsInstructions for how to use the X-VIVO™ Media Series
-
Essentials for Preparing a Transfection Experiment - Plasmid DNA - Technical Reference GuideThis document will provide you with guidelines on how to prepare quality DNA for transfections.